ESTRO 2025 - Abstract Book

S4019

Radiobiology - Tumour radiobiology

ESTRO 2025

Results: Both formulations of AuAg NPs showed high biocompatibility, with decreased viability above 100 µg/mL. In clonogenic assays, cells treated with AuAg (H 2 O+H 2 O 2 ) showed a trend of decreased survival with increasing radiation dose, though no significant difference was observed compared to controls. In contrast, AuAg EtOH NPs resulted in a significantly lower survival fraction as the irradiation dose increased (Fig. 1)

Clonogenic assay results at different radiation dose in PC3 treated with the two AuAg NPs (p < 0.05). Results are relative to the controls

Conclusion: AuAg NPs proved to be both biocompatible and effective as radiosensitizers for XRT. In vivo biodistribution results showed that these NPs act as contrast agents, allowing their localization and quantification by CT imaging. Moreover, biodistribution analysis with CT shows the NPs appeared to be capable of self-degradation, facilitating clearance from the body. Hence, our next goal is to evaluate the effects of combining NPs treatment with RT in tumor mouse models

Keywords: Alloys, Computed Tomography, X Ray Radiotheraphy

References: 1 Torresan, V., Forrer, D., Guadagnini, A., Badocco, D., Pastore, P., Casarin, M., Selloni, A., Coral, D., Ceolin, M., Fernández van Raap, M.B., Busato, A., Marzola, P., Spinelli, A.E., Amendola, V. 4D Multimodal Nanomedicines Made of Nonequilibrium Au–Fe Alloy Nanoparticles. ACS Nano. 2020 Sep 2;14(10):12840–12853. doi: 10.1021/acsnano.0c03614 2 Amendola, V., Guadagnini, A., Agnoli, S., Badocco, D., Pastore, P., Fracasso, G., Gerosa, M., Vurro, F., Busato, A., Marzola, P. Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents. J Colloid Interface Sci. 2021

4132

Digital Poster Development and validation of a hypoxia-associated gene signature in patients with uterine cervical cancer. Anubhav Datta 1,2 , Peter Hoskin 1,3,4 , Ananya Choudhury 1,3 , Luisa Vanesa Biolatti 1 1 Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom. 2 Clinical Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 3 Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 4 Clinical Oncology, Mount Vernon Cancer Centre, Manchester, United Kingdom Purpose/Objective: Uterine cervical cancer ranks fourth in incidence and mortality among women 1 . Hypoxia, a known negative prognostic factor and a radioresistant feature of solid tumours, can be evaluated via gene expression signatures 2 .